华仁药业：2025年前三季度净利润约5458万元

Company Performance - Huarun Pharmaceutical reported a revenue of approximately 976 million yuan for the first three quarters of 2025, representing a year-on-year decrease of 9.07% [1] - The net profit attributable to shareholders was approximately 54.58 million yuan, down 42.87% year-on-year [1] - Basic earnings per share were 0.0462 yuan, reflecting a decrease of 42.82% compared to the previous year [1] Market Context - As of the report, Huarun Pharmaceutical has a market capitalization of 3.9 billion yuan [2] - The A-share market has recently surpassed 4000 points, indicating a significant market resurgence after a decade of stagnation, with technology leading the market's new "slow bull" pattern [2]